Abbisko Therapeutics Co
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Abbisko Therapeutics Co sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Abbisko Therapeutics Co: 6 sponsored US clinical trials, 4 recruiting.
Abbisko Therapeutics Co sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tenosynovial Giant Cell Tumor, with 2 trials.
Upper-quartile sponsor footprint
Abbisko Therapeutics Co sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
NCT06225804
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
NCT05244551
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
NCT04906434
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NCT04192344
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
NCT05627063
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 3 | 1 |
What is open in the Abbisko Therapeutics Co pipeline
4 recruiting of 6 indexed (67% open).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Tenosynovial Giant Cell Tumor (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abbisko Therapeutics Co: open-pipeline peers nationwide
Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Abbisko Therapeutics Co sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
- Abivax S.A. · 6 trials · 33% recruiting
Sponsors near 67% open enrollment (± trial volume)
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
- Alexander B Olawaiye, MD · 67% recruiting · 3 trials
Related
What to do with this Abbisko Therapeutics Co page
6 registered trials is a research-attention snapshot, not an endorsement of Abbisko Therapeutics Co or any single study.
- 4 of Abbisko Therapeutics Co's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Tenosynovial Giant Cell Tumor is the condition Abbisko Therapeutics Co studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tenosynovial Giant Cell Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abbisko Therapeutics Co pipeline card: 6 registered trials from official public datasets.Report a data error.